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Left ventricular abnormalities in children, adolescents and young
adults with renal disease. The cardiac abnormalities that complicate
chronic renal failure and renal replacement therapy are not well charac-
terized in young people. These abnormalities are becoming more impor-
tant because successful renal transplantation has resulted in children with
end-stage renal failure living longer. Echocardiographic abnormalities of
cardiac function and structure were studied in children and young adults
(<27years old) with chronic renal failure (CRF, N = 32), end-stage renal
failure treated with chronic peritoneal dialysis (CFD, N = 10) or renal
transplantation (N = 30) or controls (N = 60). Left ventricular mass
indexed for height (LVM/Ht and LVM/Ht2'7) and body surface area
(LVM/SA), fractional shortening, measurement of left ventricular dia-
stolic function (peak E and A wave velocities and the E/A ratio) and
structural (such as valvular) abnormalities were determined by echocar-
diography. The median (and range) of LVM/Ht in the groups were control
51.8 (23.1 to 119.8), CRF 60.2 (22.2 to 135.8), CPD 80.2 (44.5 to 100.9)
and transplant group 97.8 (51.2 to 182.1) glm. The increases in LVM/Ht,
LVM/Ht27 and LVM/SA in the transplant group were significant (P <
0.01). The CRF group had significantly increased LVM/Ht27 and
LVM/SA (P < 0.01). Systolic function was not significantly different
between the groups. A significant correlation between creatinine and
LVM indexed for height was found in the CRF group. Systolic or diastolic
blood pressure could not be correlated with LVM indices in the transplant
group. Changes in diastolic function were found (increased peak A wave
velocity and decreased E/A ratios in the CRF and CPD groups, and
increased peak E wave velocity in the transplant group). The study
demonstrated that left ventricular hypertrophy is a frequent and often
severe finding in children with chronic renal failure and those treated with
renal replacement therapy. Factors other than hypertension and anaemia
are important, and evidence was found for a link between serum creati-
nine and increased left ventricular mass prior to end-stage renal failure.
the lifespan of these patients markedly and many of the serum
lipid abnormalities that predispose adults to premature cardiovas-
cular disease are present in these children [4—6]. The nature and
importance of other cardiovascular risk factors in these patients
have not been evaluated but may include hypertension, left
ventricular pressure or volume overload, anemia, acidosis, hyper-
parathyroidism, uremia and electrocardiographic abnormalities
[7—11].
Left ventricular hypertrophy (LVH) has been identified as a
major risk factor for cardiovascular mortality in adults [12—14],
especially in populations with hypertension [15, 161, or ESRF [17].
Data are scarce on the prevalence and severity of LVH in children
with renal disease, although a recent statement from the EDTA
reported that 30% of children on continuous ambulatory perito-
neal dialysis (CAPD) and 22% of transplant children had LVH on
echocardiographic examination [18].
The aims of this study were to identify the prevalence and
severity of left ventricular hypertrophy and other abnormalities of
cardiac function and structure in children and young adults with
renal impairment, end-stage renal failure treated with peritoneal
dialysis, or after renal transplantation. This study is the initial
analysis of a cohort of patients who will be followed over the
longer term.
Methods
Patient selection
Cardiovascular complications of renal failure are not infrequent
in pediatric patients with end-stage renal failure (ESRF) [1, 2].
The European Dialysis and Transplant Association (EDTA)
reported that 41% of deaths in children less than 15 years of age
with ESRF were attributable to cardiovascular causes [3]. In most
cases the deaths were sudden and unexpected and hyperkalemia
was implicated in only 17% of the deaths. Cardiovascular disease
is likely to become more important in children with renal failure
because treatment with renal replacement therapy has increased
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The study was approved by the Human Ethics Committees of
the Royal Children's Hospital (RCH) and Royal Melbourne
Hospital (RMH), Parkville. Three patient groups and a control
group were chosen. The chronic renal failure (CRF) group
consisted of patients who had a serum creatinine greater than 2
5D5 (standard deviations) above the mean for age for at least six
months and a defined cause for renal impairment. Patients treated
with chronic peritoneal dialysis (CPD) and patients who had
undergone renal transplantation (TX) formed the second and
third subject groups, respectively. The control group consisted of:
(1) children and young adults attending the renal clinics for
management of urinary tract infection or non-progressive renal
disorders, (2) siblings of recruited subjects, and (3) randomly
chosen medical students from a volunteer group to complete age
and sex matching of some of the older patients. Controls were
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excluded if there was a known history of hypertension or if they
were found to have impaired renal function.
Statistical analysis using "Power" Epicentre Software (Pasade-
na, CA, USA) was performed to determine the number of
subjects required in each group [191. The study required the
power to demonstrate a 5% difference in cardiac mass at a power
of 0.8. Thirty patients were required in each group and patients
were enrolled until at least that number was reached, except in the
CPD group where only 10 children were being treated and all
were enrolled. To minimize the potential effect of enrollment bias
in each of the other patient groups each patient group studied
consisted of the youngest patients treated at the renal clinics who
consented to enter the study. This selection procedure determined
that the oldest patient was 27 years old.
On enrollment, all subjects and controls were interviewed and
examined by one of the investigators (LMJ). The following data
were recorded: age, gender, underlying renal disease, date of
transplantation; type of renal transplant (living related or cadav-
eric), medications, family history of cardiac disease in parents and
grandparents, history of smoking in older patients. Clinical find-
ings recorded were height (Ht), weight, blood pressure, pubertal
status and any abnormal cardiovascular findings. Body surface
area (SA) was calculated according to 0.0001 X 71.84 X
(weight)°425 x (Ht)° [201. The following investigations were
performed: hemoglobin, urea, electrolytes, creatinine, albumin,
calcium, phosphate, alkaline phosphatase and intact parathyroid
hormone.
No subject in the CPD group had an episode of peritonitis at
the time of the study. Nine were treated with CAPD and one with
continuous cyclic PD. One of the CAPD subjects had had two
cadaveric renal transplants; one failed due to rejection and the
other failed due to cyclosporin associated microangiopathic
thrombopathy. Three patients were treated with erythropoietin
and one was treated with recombinant human growth hormone
(rhGH).
In the transplant group 9 patients had received living related
grafts, and 21 patients had cadaveric grafts. Four had had a
previous transplant and one subject had had two previous grafts.
The median time following transplantation at the time of study
was 2.3 years (range 0.3 to 6.8 years). Two of the transplant
subjects had known renal artery stenosis on Doppler ultrasound,
and one had an arterio-venous fistula at the time of study.
Immunosuppressive therapy following renal transplantation con-
sisted of cyclosporin A (all patients), azathioprine (29 patients)
and prednisolone (18 patients, median dose 0.11 mg/kg/day, range
0.03 to 0.6 mg/kg/day). Diltiazem was used as a routine treatment
post-transplantation since 1990 to allow lower doses of cyclospo-
rine to be given. Sixteen patients were treated with diltiazem. Two
patients were treated with rhGH.
Four of the CRF group were treated with rhGH and four were
treated with erythropoietin.
Echocardiography
Echocardiographic studies were performed at both the RCH
and RMH. Six patients had studies performed at both Hospitals
on the same day to establish a concordance of echocardiographic
technique at both centers. The echocardiography techniques were
standardized at the two centers by an investigator (LG). Subse-
quently all studies were videotaped and checked by LG.
Echocardiography was performed using Hewlett-Packard So-
nos 1000 phased array ultrasound unit with 2.5, 3.5 and 5.0 MHz
transducers. Measurements were made according to the recom-
mendations of the American Society of Echocardiography using a
leading edge to leading edge convention [21]. Left ventricular
mass (LVM) was also determined using the Penn convention [22]
to check results for the older children, but not used for analysis as
it tended to underestimate LVM in the younger children.
The following echocardiographic data were collected: left ven-
tricular end diastolic dimension (LVIDD), left ventricular end
systolic dimension (LVISD), left ventricular posterior wall thick-
ness (PWT), interventricular septal thickness (IVS), aortic root
(AR) diameter, left atrial (LA) dimension. Other measurements
were fractional shortening and diastolic mitral inflow measuring
peak E wave flow (early filling) and peak A wave flow (late filling)
and E:A ratio. Diastolic initial inflow velocities were measured by
pulsed wave Doppler at the tips of the mitral valve leaflets, with
the opening click of the mitral valve just audible. An average of a
minimum of three measurements was taken. Measurements were
always taken at the end of expiration with normal quiet breathing.
Valvular abnormalities were noted when present. Left ventricular
mass was determined by M-mode echocardiography using the
following formula: LVM(g) =0.8{1.04[(LVIDD + PWT + IVS)3
— (LVIDD)]3} + 0.6 [23]. Left ventricular size was measured at
or just below the tips of the mitral valve leaflets at the largest left
ventricular internal dimension. LVIDD and PWT measurement
were made at end-diastole.
Linear dimensions (LVIDD, LVISD, PWT, IVS, aortic root
diameter and LA dimension) were compared using direct mea-
surements and measurements indexed to SA (0.5) as recom-
mended by Gutgesell and Rembold [24].
Direct linear measurements (LVIDD, LVISD, PWT, IVS, LA,
AR diameter) were further compared and defined as abnormal if
the measurement fell above the 95th confidence interval for body
SA [25].
LVM was indexed to height and SA. Obesity has been associ-
ated with increased left ventricular mass and indexing for height
has been thought to give better indication of true LVH than does
indexing for SA in obese children [26—28].
LVM was also indexed according to the allometric regression
equation described by de Simone et al [28]. This indexes LVM by
Ht27, which produces a linear relationship. They have described
95% confidence limits for this relationship.
Left ventricular hypertrophy (LVH) was defined using a num-
ber of criteria: for children 6 to 16 years, LVH was defined as
LVM greater than the 95th centile prediction interval for age, sex
and height according to Malcolm et a! [29]. For children less than
six years, very little data are available concerning normal left
ventricular mass for age and sex. A LVM of 60.1 g (males) and
62.0 g (females) were used to determine LVH in these younger
children, These values are given for six years old children on the
5th height centile for the 95th centile for LVM [29]. This means
that some very young children with LVH may not have been
identified as having LVH. For children 16 years and over, LVH
was defined as LVM greater than the 95th centile for sex as
defined by Daniels et al [26].
LVH was also defined as measurements greater than the 95%
confidence limit following indexing of LVM by Ht27 [28]. Direct
measurements were compared between subjects and controls for
LVM, LVM/Ht, and LVM/Ht27. The proportion of subjects with
LVM, LVM/Ht and LVM/Ht27 were also compared.
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Table 1. Causes of renal disease in the subject groups
Renal disease CRF CPD Transplant
Obstructive uropathy 9 1 3
Dysplasia/hypoplasia 5 2 5
Reflux nephropathy 10 1 9
Glomerulonephropathies
Crescentic nephritis 1
FSGS 3 3
Mesangial sclerosis 1
IgA nephropathy 1
MPGN 1 1
Congenital nephrosis 1 1
Hemolytic uremic syndrome 1 1
Cystinosis 1
Medullary cystic disease 1 2 1
Renal vein thrombosis I
Oxalosis 1
Branchio-oto-renal syndrome 1
Other 1 3
Abbreviations are: FSGS, focal and segmental glomerulosclerosis;
MPGN, membrano proliferative glomerulonephritis.
Table 2. Results of blood pressure recordings and use of anti-
hypertensive medication according to subject group
Controls CRF CPD Transplant
N 60 32 10 30
Blood pressures
Systolic BP mm Hg 100 107 105 120
Diastolic BP mm Hg
(80—140)
70
(50—95)
(80—140)
70
(50—90)
(90—130)
70
(60—100)
(90—150)
80
(55—100)
Anti-hypertensive drugs
Nil 60 24 7 15
One anti-hypertensive 0 5 0 2
Two anti-hypertensives 0 3 3 9
>Two anti-hypertensives 0 0 0 4
ACE inhibitors 0 4 1 1
/3 adrenegic blocker 0 3 3 14
Ca2 channel blocker 0 1 2 10
Prazosin 0 0 0 3
Results are expressed as median (range). Abbreviation is ACE, angio-
tensin converting enzyme.
LVM/Ht and LVM/SAwere regressed against age and the
groups compared. Twenty-six age and sex matched controls were
taken from the total control group and compared with the
transplant group to avoid sex and age differences biasing the
results.
Statistical analysis
Data were evaluated by Kruskal-Wallis and Mann Whitney
U-tests to determine differences between groups. Comparison of
proportions were performed using chi-squared analysis of 2 X 2
contingency tables. Correlations were sought using the Spearman
correlation test.
Tests of parallelism comparing two regression lines were per-
formed according to Kleinbaum, Kupper and Muller [30] to
control for the effect of age and sex on measurement of LVM,
LVM/Ht and LVM/SA.
Linear regression analysis was performed to determine associ-
ations between LVM and clinical data and then multiple linear
regression was used to determine inter-relationships between
correlations found.
Table 3. Demographics of subjects according to subject group
Controls CRF CPD Transplant
N 60 32 10 30
Age years
Males/females
11.4
(0.6—28.1)
25/35
10.1
(1.5—16.9)
22/10
13.7
(1.8—17.5)
4/6
16.0
(3.8—25.6)
21/9
Height cm 142.9 126.3 145.0 157.4
Weight kg
(69.0—192.0)
36.9
(79.0—174.7)
26.2
(81.5—167.5)
31.0
(92—176.5)
50.5
BSA m2
(8.9—88.0)
1.20
(0.40—2.15)
(10.8—53.2)
0.95
(0.47—1.63)
(9.6—76.3)
1.15
(0.45—1.72)
(12.1—83.0)
1.49
(0.57—1.96)
Results are expressed as median (range). BSA: body surface area.
Table 4. Laboratory results for subjects in the study by group
Controls CRF CPD Transplant
N 60 32 10 30
Hbg/dl 13.3 115b 975 ll9
Urea mmol/liter
(9.0—16.1)
4.5
(2.5—7.7)
(6.8—15.1)
15.0k'
(6.2—48.5)
(7.9—13.6)
l8.2'
(11.2—30.2)
(8.7—15.5)l13
(5.7—28.4)
Creatinine mmol/liter 0.06
(0.03—0.12)
0.21a
(0.06—0.96)
0.62a
(0.33—1.2)
0.12'
(0.04—0.27)
Calcium mmol/liter 2.38 2.30 2.42 2.41
Phosphate mmol/liter
(2.17—2.57)
1.4
(1.95—2.51)
l.7'
(2.20—2.85)
1.6
(2.20—2.53)
1.4
Albumin glliter
iPTH nglliter
(0.6—2.1)
44
(38—49)
25
(12—97)
(1.2—2.6)42
(24—48)
98h
(19—1132)
(1.2—2.6)
38b
(27—43)
70
(12—1307)
(0.9—2.0)
395
(31—45)66
(14—140)
Results are expressed as median (range). Abbreviations are: Hb,
hemoglobin; iPTH, intact parathyroid hormone.
a p < 0.01, 5P < 0.001, for subject groups compared with the control
group.
Multiple logistic regression analysis was used to assess the effect
of anti-hypertensive medications on LVM in the TX group. LVH
was the dependent variable, defined as LVM/Ht or LVM/Ht27
values greater than the 95th centile. LVH was tested against the
following independent variables: age, Ht, weight, urea, creatinine,
albumin, hemoglobin, systolic and diastolic blood pressures and
treatment with antihypertensive medications.
A P value of < 0.05 was considered significant except where
multiple comparisons were performed when a P value < 0.01 was
considered significant.
Results
The causes of the renal diseases of the subjects in the CRF,
CPD and transplant groups arc listed in Table 1, and blood
pressures and anti-hypertensive medications at the time of enrol-
ment are given in Table 2. Demographic and anthropoimetric
data on subjects and controls are given in Table 3.
Laboratory data
The results of biochemical and hematological investigations are
shown in Table 4. Serum concentrations of urea and creatinine
were significantly increased (P < 0.001) in all three subject groups
when compared to their respective controls. Hemoglobin concen-
trations less than 10 g/dl were present in 8 (25%) of the CRF
group; 5 (50%) of the CPD group and 3 (10%) of the transplant
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Table 5. Results of echocardiography
Controls CRF CPD Transplant
N 60 32 10 30
1. Linear dimensions
LVIDD cm
N > 95th centile
4.3 (2.6—5.8)
7
4.1 (2.5—5.5)
10h
4.4 (2.7—4.6)
3
4•8b (3.2—6.2)
14"
LVIDD/SA°5 40.0 (3.1—4.6) 4.0 (3.5—4.8) 3.9 (3.3—4.8) 4.1 (3.4—4.8)
LVISD cm 2.7 (1.7—3.9) 2.6 (1.7—3.3) 2.6 (1.6—3.7) 3.1 (2.1—4.7)
N > 95th centile 8 6 2 11
LVISD/SA°5
IVS cm
N> 95th centile
2.5 (1.9—3.0)
0.7 (0.4—1.0)
4
2.6 (1.6—3.2)
0.7 (0.4—1.2)
8
2.3 (2.1—3.6)
0.9 (0.6—1.1)
4"
2.5 (2.0—3.4)
0.9" (0.5—1.2)
13a
IVS/BSA°5
PW cm
N> 95th centile
0.6 (0.4—1.0)
0.6 (0.3—1.0)
0
0.7" (0.4—1.1)
0.6 (0.4—1.2)
4
0.8 (0.4—1.6)
0.8a (0.4—1.2)
2
08b (0.6—0.9)
0.9" (0.5—1.2)
10"
PW/SA'5 0.6 (0.4—0.7) 0.6a (0.4—1.1) 0.7" (0.5—1.0) 0.8" (0.5—1.0)
AR cm 2.3 (1.3—3.5) 2.5 (1.7—3.4) 2.4 (1.9—3.0) 2.5 (1.7—3.4)
N > 95th centile 6 9' 4 6
AR/SA°5
LA cm
2.2 (1.6—2.9)
2.8 (1.7—4.1)
2.3" (1.9—3.0)
2.7 (1.6—3.9)
2.5 (2.1—3.4)
3.2 (2.0—3.6)
2.1 (1.8—2.8)
3.4" (2.1—4.6)
N > 95th centile 0 2 1 5
LA/SA°5 2.7 (1.4—3.6) 2.7 (1.2—4.0) 3.0 (2.1—3.9) 2.8" (2.4—3.5)
2. LVM
LVM g
N > 95th centile
72.2 (16.4—219.7)
10
75.8 (17.5—204.9)
11
120.3 (36.0—168.9) 145.6" (49.2—313.3)
17b
LVM/Ht glm
N > 95th centile
51.8 (23.1—119.8)
7
60.2 (22.2—135.8)
4
80.2a (44.5—100.9)
3
97•8b (51.2—182.1)
15"
LVM/Ht17 gIm27
N> 95th CI
33.1 (18.7—68.6)
3
39.2 (25.0—68.1)"
7b
42.6" (30.8—100.8)3 52.6" (27.2—72.4)19"
3. Systolic function
FS % 3.7 (25—48) 36(27—57) 36(18—45) 37(21—46)
4. Diastolic function
E wave mIs
A wave mIs
E/A ratio
0.9 (0.7—1.4)
0.5 (0.2—0.9)
1.8 (1.2—5.0)
1.0 (0.5—1.2)
O.6' (0.3—0.9)
l.6' (1.3—2.7)
0.95 (0.6—1.3)
0.65" (0.6—0.9)
1.5' (0.9—2.2)
1.1" (0.7—1.7)
0.6 (0.3—0.8)
2.0 (1.1—4.3)
Linear dimension measurements are expressed as (i) median (range) and the data has been compared using the Mann Whitney U test; (ii) the number
of patients in each group with results greater than the 95th centile (compared using chi-square analysis); and (iii) indexed to SA°5, tabulated as median
(range), and compared using the Mann Whitney U test. Similarly, the LVM data has been tabulated as (i) direct measurements and measurements
indexed to Ht and Ht27 (compared between groups using the Mann Whitney U test), and (ii) the number of patients with results over 95th centile (or
greater than the upper limit of the 9th confidence interval in the case of LVM/Ht27). The fractional shortening and diastolic function is reported as
median (range) and compared using the Mann Whitney U test. Analysis of LVM/Ht and LVM/SA as a function of age are shown in Figure 1.
P < 0.05, hP < 0.01 for the comparison of each patient group with the control group
group, one of whom had a hemoglobinopathy. Serum albumin
concentrations were significantly decreased in the three subject
groups compared to the controls. Two of the CRF group had
heavy proteinuria due to focal glomerulosclerosis, but they were
not nephrotic and angiotensin converting enzyme (ACE) inhibi-
tors were used to control proteinuria. The exclusion of these two
patients did not change the result of the tests of significance
reported in Table 4. None of the transplant or dialysis subjects
had nephrotic range proteinuria. Serum concentrations of intact
parathyroid hormone were increased in the CRF and CPD groups
compared to the control group.
Cardiac findings
Clinical. Two subjects had treated cardiac disease. A 21-month-
old boy with renal impairment had had pulmonary valve stenosis
treated by balloon angioplasty in early infancy with no significant
residual pulmonary stenosis. An eight-year-old male with obstruc-
tive uropathy treated with CAPD had had a complete repair of
tetralogy of Fallot at three years of age and had mild residual
pulmonary valve regurgitation, with no significant pressure gradi-
ent across the right ventricular outflow tract.
No other children had clinical evidence of structural cardiac
abnormalities.
Echocardiography. At the time of the study all subjects and
controls had a normal heart rate and rhythm. None of the subjects
was dehydrated.
1. Linear dimensions. The results for LVIDD, LVISD, IVS, PW,
AR and left atrial dimensions are given in Table 5. A consistent
difference between the left ventricular internal dimensions of the
four groups was not found. In contrast, the wall thickness mea-
surements (IVS and PW) were greater in the CPD and TX groups
whether analyzed by direct comparison of measurements or
comparison of measurements indexed for surface area. There is
an increase in these measurements indexed for surface area from
the control group to the CRF group to the CPD and TX groups.
The number of subjects with an increased AR dimension was
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increased in the CRF and CPD groups. AR dimension indexed for
SA°5 was increased in CRF group. The aortic root dimension for
the transplant group was similar to that of the control group.
The left atrial dimension was increased in the transplant group,
and in the CPD group when indexed for SA°5.
In all individuals the IVS:PW ratio was less than 1.5:1 with an
average of 1,1:1, showing that the LV enlargement was concentric
rather than asymmetric.
2. Left ventricular mass. Echocardiographic measurements and
comparisons between groups are shown in Table 5. LVM indexed
for Ht and for SA plotted against age are shown in Figure 1.
Even though 11.6% of the control group had LVM/Ht greater
than the 95th centile, the proportion of transplantation subjects
with LVM/Ht greater than the 95th centile (50%) was significantly
greater (x2 = 15.912, P < 0.001). All of the control subjects with
LVM/Ht greater than the 95th centile were young adults who
were active participants in regular physical exercise, which may
explain their LVH and hence be a physiological response. The
number of controls with LVH decreased to 3 (5%) using LVM/
Ht27 (as recommended by De Simone et al [28]). The proportion
of subjects with a value of LVM/Ht27 above the 95% confidence
interval was significantly increased in all subject groups compared
to the control group: CRF, 2 6.134, P = 0.0075; CPD, x2
6.836, P = 0.005; TX, = 36.848, P = 0.000). Further,
LVM/Ht27 was increased in all subject groups compared to
controls (Table 5).
Transplant patients were compared with age and sex matched
controls. The transplant patients had significantly greater LVM
and LVM/Ht measurement than matched controls [LVM, 145.6 g,
49.2 to 313.3 g (mean, range) and LVM/Ht, 97.8 g/m, 51.2 to 182.1
glm in transplant patients; LVM, 115.0 g, 28.0 to 218.7 g and
LVM/Ht 70.2 g/m, 25.9 to 119.8 g/m for age and sex matched
controls; P < 0.05 and <0,01, respectively). The youngest trans-
plant recipient's LVM/Ht (51.2 g/m) was twice that of the
appropriate control (25.9 g/m).
Regression analysis was performed to determine if a significant
difference existed between the subject groups and controls when
the effect of age and sex was controlled on LVM indexed for
height (Fig. 1). Using a test of parallelism to assess difference,
LVM/Ht was significantly different when comparing controls
(LVMIHt = 30.3 + 2.28 age) with CRF (LVM/Ht = 14.7 to 5.29
age), P = 0,0002, and when comparing controls with renal
transplant recipients (LVMIHt = 37.2 + 4.25 age), P = 0.005. A
difference was not found between controls and CPD subjects
possibly because of the small number of CPD patients. Similarly,
a significant difference was found in LVM/SA between controls
and CRF subjects (controls, LVM/SA = 53.6 + 1.09 age; CRF,
LVM/SA = 38.3 + 4.46 age; P = 0.0001) and between controls
and transplant subjects (TX, LVM/SA 37.2 + 4.25 age; P <
0.001).
There was no association in the transplant group between
LVM/Ht and time following transplantation (r 0.113, P> 0.05).
In summary, the transplant group had significantly higher LVM
measurements compared to the control group whether or not: (1)
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Fig. 1. LVM indexed for height and body surface
a area versus age. In A and C the control group
age is shown (dotted line for the control group
The regression line of the LVM indices against
A
.. and solid line for the CRF group). In B and D100
150 (LI) are compared with the CRF group (•).
a the controls are represented by the open
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a closed triangles (A), and the regression of the50 aa: LVM indices against age by the dotted line forcontrols and the solid line for the transplant
group. The equations of the regression lines are0 given in the text. The tests of parallelism
0 10 20 30 0 10 20 30 comparing the two regression lines in each of
Age, years Age, years the four plots were significantly different (P <0.01).
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unindexed LVMs (Table 5); (2) LVM/Ht, LVM/Ht27 (Table 5) or
LVM/SA (Fig. 1); (3) the number of patients above the 95th
centile for LVM, LVM/Ht or LVM/Ht27 (Table 5); (4) age and
sex matched controls were compared, or (5) regressions of
LVM/Ht and LVM/SA on age were compared (Fig. 1).
3. Fractional shortening. Despite the increase in cardiac mass,
the systolic function in the patient groups, as reflected by the
fractional shortening, was not different to that in the controls. Two
children were found to have significantly impaired cardiovascular
function. One, a 13-year-old boy treated with CAPD, had a
fractional shortening of 18%. He was poorly compliant with
medication and his dialysis prescription. The other child, a
four-year-old boy with a cadaveric renal transplant and hyperten-
sion had a fractional shortening of 21%.
4. Diastolic dysfunction. Although the results of E wave peak
velocity and A wave peak velocity and the EtA ratio were within
the normal range for all subject groups, an increase in the A wave
peak velocity and a reduction in the EtA ratio were found in the
CRF and CPD groups compared to controls. An increase in the E
wave peak velocity was found in the transplant group, but the E/A
ratio was not significantly increased. No association could be
demonstrated between changes in E wave velocity, A wave
velocity or EtA ratio in subjects with or without LVH and no
correlation between these values and either LVM/Ht or LVM/
Ht27 (Spearman correlation test) was found.
5. Structural lesions. Echocardiography did not reveal any
structural or valvular lesions apart from the two children with
known structural lesions described above.
Clinical correlations
Correlations were sought between clinical variables and both
LVM/Ht and LVMIHt27. The results of both analyses revealed
the same significant correlations and the data relating to correla-
tion with LVM/Ht have been detailed here. Linear regression
analysis of left ventricular mass indexed for height correlated with
age, height and weight for each group except the CPD subject
group where no significant correlation could be demonstrated. In
the control group there was a moderately strong correlation
between LVM/Ht and hemoglobin (r = 0.545, P < 0.02) and
creatinine (r = 0.767, P < 0.02), but this was not evident in the
subject groups. Systolic and diastolic blood pressures were mod-
erately correlated with LVM/Ht for controls (systolic, r =0.641,
P < 0.02; diastolic, r = 0.458, P < 0.02), for CRF (systolic, r =
0.674, P < 0.02; diastolic, r = 0,710, P < 0.02) and for CPD
(systolic, r = 0.881, P < 0.01; diastolic, r = 0.778, P < 0.05). No
significant correlation was demonstrated between LVM/Ht and
systolic (r = 0.456) or diastolic blood pressure (r = 0.276) for the
transplant group. The correlations may have been related to
normal age-related changes, and multiple regression analysis was
undertaken to examine the interdependence of the factors found
on linear regression analysis.
Multiple regression analyses of LVM/Ht against the compound-
ing variables of age, height, weight, hemoglobin, urea, creatinine
and systolic and diastolic blood pressures were performed for the
controls and each subject group. For the control group, LVM/Ht
was significantly associated with age (P = 0.019), height (P
0.027) and weight (P = 0.001). For CRF subjects, an association
was present between creatinine and LVM/Ht (P = 0.014). No
associations with LVM/Ht could be demonstrated in the CPD
group. Only weight was associated with LVM/Ht in the transplant
group (P = 0.025).
The effect of medications on LVH was examined. Glucocorti-
coids are known to be associated with LVH. Eighteen of 30 of the
TX group were the only subjects taking this medication. There
was no correlation between LVM/Ht and prednisolone dosage
(mg/kg/day) in the TX group (r = 0.38, P > 0.05) and no
difference in LVM/Ht between those who were or were not on
prednisolone ( = 1.58, P > 0.05). Similarly, in the TX group
again, there was no correlation between LVM/Ht and cyclospo-
rifle dose (r = 0.093, P > 0.05). No associations between the
administration of antihypertensive medication and LVM/Ht and
LVMIHt27 were found within the transplant group using multiple
logistic regression analysis. The number of patients treated with
any individual antihypertensive drug (or drug class) was insuffi-
cient for analysis.
Discussion
Some aspects of the study design and analysis should be
discussed. Firstly, the comparison of patients over the age and size
range presented in this study posed analytical problems. The data
were statistically analyzed to overcome these problems. Tests of
parallelism have been used that compare the change in a variable
over age between controls and subject group patients. In addition,
the number of results greater than the 95th centile for the normal
range was compared between the control and subject groups
(using the test). Secondly, there is an association between
congenital heart disease and developmental anomalies of the
kidneys and urinary tract. The possibility of selection bias in this
cross-sectional study was minimized by selecting all children on
peritoneal dialysis and the youngest patients with chronic renal
failure or a renal transplant at both treatment centers.
There is a paucity of normative data in children for left
ventricular mass measurement by echocardiography. Additionally,
there is not universal agreement in the way data should be
presented. Daniels et al [26] studied 334 young persons between
the ages of 6 and 23 and determined the distribution of LVM,
LVM corrected for height and LVM corrected for body surface
area according to sex. No data were provided for LVM according
to age. De Simone et al [28] determined 95% confidence intervals
for LVM according to sex and height in 444 individuals ranging
from four months to 23 years of age. They also determined
allometric relationships between LVM and Ht, weight and SA. In
their studies the indexing of LVM to Ht27 reduced the variability
in LVM caused by weight differences better than indexing LVM to
Ht or SA. Recently Malcolm et al [29] have provided data on
LVM for normal U.S. children between the ages of 6 and 16
according to age, sex and height. Vogel, Stahl and Buhlmeyer [31]
attempted to correct the lack of data available for children less
than six years of age and investigated 67 children less than eight
years of age and provided mean LVM for four age groups
(newborns, infants, I to 4 years and 5 to 8 years) but without
consideration for age or height. It is well recognized in the
pediatric age range that age, height and weight are all significantly
associated with LVM. Although children with renal disease are
frequently short, there was no significant difference between
subject groups and controls for height, so we do not believe that
the increase in LVM indexed for height is explained by height
differences alone. Similarly, our data demonstrate for CRF and
TX study groups that the increase in LVM is not purely a function
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of increasing age. In view of these considerations and the lack of
a universally applicable reporting form, we chose to present the
dimensional and LVM data in a number of ways and indexed to
SA, Ht and Ht2'7. The differences between the subject groups and
controls were so robust that a similar pattern of results was found
no matter how the data were analyzed.
This study investigated a relatively large group of children and
young adults across the spectrum of chronic renal failure and
end-stage renal failure. Left ventricular mass indexed for height
was significantly increased in the CPD and transplant subject
groups. Further analysis using LVM/Ht27 confirmed this finding
and demonstrated an increase in LVM in all three subject groups.
Importantly, 22% of the CRF group, 30% of the PD group and
63% of the transplant group had LVM/Ht27 greater than the sex
appropriate 95th centile. Previous studies of LVH in pediatric
patients with renal disease have investigated small numbers of
children treated with peritoneal dialysis [32] or hemodialysis [33,
34]. Hemodialysis can alter cardiovascular function due to the
presence of increased cardiac output associated with an arterio-
venous fistula and to the larger changes in intravascular volume
the patients experience pre- and post-dialysis [35]. These studies
also found a high incidence of LVH. Our findings in the PD group
differ to those of Morris et al [32] who found that 12 of 13 children
treated with PD [12] or HD [1] had LVH which was mainly
attributable to asymmetric septal hypertrophy. Our subjects had
concentric ventricular hypertrophy. All of the children Morris et
al [32] studied were anemic (Hb <9.0) and they have since shown
reduction in left ventricular mass following treatment with recom-
binant human erythropoietin [33].
Left ventricular hypertrophy has been identified as a strong
independent predictor of cardiovascular morbidity and mortality
in the adult population [12—14], and in adult populations with
hypertension [16] or coronary artery disease [36]. The risk of
premature cardiovascular disease or death in the otherwise nor-
mal child is small, and it is not surprising that LVH as a
cardiovascular risk factor has not been studied in children.
A number of studies of adult patients with ESRF has shown
that the presence of left ventricular hypertrophy in these patients
is associated with an increased risk of morbidity and mortality [17,
37, 38]. There is also evidence that cardiovascular disease is a
cause of death in the pediatric ESRF population [3, 6]. The
contribution of LVH to that morbidity is unknown. The potential
importance of detection of LVH in pediatric renal patients is that
it may be responsive to treatment in many patients. Reversible
factors associated with left ventricular hypertrophy include hyper-
tension, anemia and obesity. Better control of uremia, hyperlip-
idemia, high angiotensin II concentrations, and hyperparathyroid-
ism may be possible in the patient with renal disease, and be of
benefit in controlling LVH.
Left ventricular hypertrophy was found most frequently after
renal transplantation. Renal transplantation is associated with
correction of uremia, anemia and secondary hyperparathyroidism.
These effects would be expected to reduce the severity of LVH.
The transplant patients were more likely to be hypertensive than
those in the other groups. A greater proportion of individuals in
this group required anti-hypertensive medication and more than
one medication was usually required. Hypertension usually causes
concentric ventricular hypertrophy which was found in this study.
However, this study did not reveal a significant correlation
between blood pressure and LVM/Ht or LVM/Ht27 in the
transplant group. Furthermore the AR diameter was not in-
creased in the TX group (it tended to be smaller than in the CPD
and CRF groups). In hypertensive heart disease the AR is usually
dilated. Fagard et al [39] on reviewing the literature found that
correlation coefficients (r) between LVM or LVM/Ht and blood
pressure in the normal population were commonly less than 0.5,
and that this was true whether the blood pressure was recorded in
clinic, with ambulatory recording or with repeated measurements
over a 30 year period. Thus, this study suggests that hypertension
is not the dominant cause of LVH in the post-renal transplant
patient.
The effect of medication may have been important in causing
LVH. Half of the transplant group were treated with antihyper-
tensive drugs and only one of these patients received an angio-
tensin converting enzyme (ACE) inhibitor. Renin-angiotensin-
aldosterone mediated hypertension is high in transplant patients
originating from native kidneys, graft artery stenosis or chronic
rejection [40]. There is a significant body of evidence in experi-
mental animals that renin-angiotensin can cause myocardial hy-
pertrophy and fibrosis [41—43]. Angiotensin converting enzyme
inhibitors would be expected to block this effect. This class of drug
is often avoided after transplantation because of the possibility of
there being a relative stenosis in the single graft renal artery, in
which case renal function may be impaired with use of an ACE
inhibitor. This mechanism could be relevant to the occurrence of
LVH in the post-transplant patient. This study was too small to
test this hypothesis.
Eighteen of the TX group were on prednisolone at the time of
the study and all had prednisolone in the first six months following
transplantation. Despite the lack of a clear relationship between
LVM indexed to Ht or Ht2'7, there may have been a permissive or
additive effect of steroid as reported in infants with lung disease or
studies on exercise-induced cardiac hypertrophy [44, 45]. In
animal studies gluococorticoids have induced left ventricular
hypertrophy that resolves with time despite on-going steroid use
[46].
There is evidence uremia may cause LVH. An important
finding of this study was the correlation found between serum
creatinine and LVM/Ht in the CRF subjects by both linear and
multiple regression analyses. This association suggests that some
aspect of renal failure per se is involved in increasing LVM. There
are several reports of improvement in cardiac function and
decreasing cardiac size after renal transplantation [47—491. Au-
topsy findings in uremic adults without coronary artery disease
have shown diffuse intermyocardiocytic fibrosis [50]. Uremia was
associated with cardiac fibrosis and the duration of uremia
correlated with the severity of the fibrosis. Renal transplant
recipients had less severe diffuse intermyocardiocytic fibrosis than
patients with advanced chronic renal failure, suggesting some
improvement with correction of uremia [50]. These reports refer
to adults with renal failure and the factors involved in causing
resolution of this uremic cardiomyopathy were obviously out-
weighed by factors causing LVH after renal transplantation in
children. Experiments in uremic rats have shown myocardial
hypertrophy and diffuse intermyocardiocytic fibrosis [51, 521. The
degree of fibrosis was greater in uremic rats when compared with
non-uremic hypertensive rats. Treatment with angiotensin con-
verting enzyme inhibition for three months failed to decrease the
degree of myocardial fibrosis, indicating that other factors are
important in the development of intermyocardiocytic fibrosis [52].
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A reduction in myocardial capillary density has been described in
uremic rats [53]. The combination of interstitial fibrosis and a
reduction in capillary density may cause restrictive changes in
myocardial compliance and ischemia.
Differences in diastolic function were found between the con-
trol and subject groups. The left ventricular peak E wave velocity
corresponds to the time of minimum left ventricular pressure in
diastole when there is a short period of trans-mitral valve pressure
difference, after the opening of the mitral valve [54]. The peak A
wave velocity corresponds to trans-mitral flow with atrial contrac-
tion. It should be noted that the results were all within the normal
range for each group and the clinical significance of the abnor-
mality found is unclear. In the CRF and CPD groups the peak A
wave velocity was increased so that the EtA ratio was reduced, a
pattern seen in abnormal myocardial relaxation [55]. Similar
results were found in a study of 11 pediatric patients treated with
hemodialysis and 14 with peritoneal dialysis [56]. In the transplant
group the peak E wave velocity was increased and the EtA ratio
tended to be higher despite the more frequent finding of LVH in
this group. This may be a reflection of recovery of diastolic
function in this group, if there is a reduction in the degree of
diffuse intermyocardiocytic fibrosis in the heart following trans-
plantation as suggested above. The assessment of diastolic abnor-
malities is affected by many factors including heart rate, age,
afterload, and respiratory phase [54, 55]. Thus, the results are
suggestive of diastolic dysfunction, but further studies examining
the slope of the deceleration phase and the deceleration time with
consideration of the patient's age, heart rate and respiratory rate
need to be performed. Follow-up studies of patients developing
LVH may reveal a relationship between changes in left ventricular
diastolic filling with LVM as found in a canine model [57].
In conclusion, this study demonstrates that left ventricular
hypertrophy is a frequent finding in children with renal impair-
ment or ESRF. The degree of hypertrophy is often severe,
particularly following transplantation. The finding of increased
LVM could not be directly associated with hypertension even
though hypertension was commonly found after transplantation,
suggesting that other factors may be more important. The finding
of LVH and increased LVM on trans-thoracic echocardiography
warrants careful assessment of all potential correctable factors
that may contribute to LVH, particularly anemia, obesity and
hypertension. Prospective long-term follow-up studies currently in
progress are required to determine the significance of increased
LVM in premature cardiovascular morbidity and mortality among
pediatric patients with renal disease.
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